Armata Pharmaceuticals (ARMP) Revenue (2016 - 2020)
Quarterly results put Revenue at $31000.0 for Q2 2020, changed N/A from a year ago — trailing twelve months through Jun 2020 was $117000.0 (changed N/A YoY), and the annual figure for FY2017 was $115000.0, down 55.77%.
Armata Pharmaceuticals has reported Revenue over the past 6 years, most recently at $31000.0 for Q2 2020.
- Revenue reached $31000.0 in Q2 2020 per ARMP's latest filing, up from $20000.0 in the prior quarter.
- Across five years, Revenue topped out at $106000.0 in Q1 2016 and bottomed at $20000.0 in Q4 2017.
- Median Revenue over the past 3 years was $29000.0 (2016), compared with a mean of $45111.1.
- The largest annual shift saw Revenue plummeted 82.81% in 2016 before it surged 31.03% in 2017.
- Over 3 years, Revenue stood at $22000.0 in 2016, then decreased by 9.09% to $20000.0 in 2017, then surged by 55.0% to $31000.0 in 2020.
- Business Quant data shows Revenue for ARMP at $31000.0 in Q2 2020, $20000.0 in Q4 2017, and $38000.0 in Q3 2017.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | - |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | 306.30 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 2.99 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 3.61 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 1.17 Bn |
| 10 | Armata Pharmaceuticals | 301.92 Mn | 297.17 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2020 | 31,000.00 |
| Dec 31, 2017 | 20,000.00 |
| Sep 30, 2017 | 38,000.00 |
| Jun 30, 2017 | 28,000.00 |
| Mar 31, 2017 | 29,000.00 |
| Dec 31, 2016 | 22,000.00 |
| Sep 30, 2016 | 29,000.00 |
| Jun 30, 2016 | 103,000.00 |